Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies Meeting Abstract

  

Authors:	Stein, E.; Tallman, M.; Pollyea, D. A.; Flinn, I. W.; Fathi, A. T.; Stone, R. M.; Levine, R. L.; Agresta, S.; Schenkein, D.; Yang, H.; Fan, B.; Yen, K.; Botton, S. D.
Abstract Title:	Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
Meeting Title:	105th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title:	Cancer Research
Volume:	74
Issue:	19 Suppl.
Meeting Dates:	2014 Apr 5-9
Meeting Location:	San Diego, CA
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2014-10-01
Language:	English
ACCESSION:	WOS:000349910205028
DOI:	10.1158/1538-7445.am2014-ct103
PROVIDER:	wos
Notes:	Meeting Abstract: CT103 -- 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 05-09, 2014 -- San Diego, CA -- S -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/74743